Targeting protein could lead to new treatments for mouth cancer

July 3, 2012
Targeting protein could lead to new treatments for mouth cancer

(Medical Xpress) -- A protein that is overactive in mouth cancers and encourages tumours to grow could be a target for new treatments for the disease. The study is published in this week’s Cancer Research.

Cancer Research UK scientists have found that the FRMD4A protein is permanently switched on in cancer, and the higher the levels the more likely the disease is to spread and return.

By blocking FRMD4A, the scientists were able to stop cancers growing and spreading, and increased survival of mice with the cancer.

Dr Stephen Goldie, who carried out this work at Cancer Research UK’s Cambridge Research Institute, said: “What’s really exciting about this research is that we already have potential drugs that can be used to target this protein or compensate for the effects that it is having.

“These drugs could offer new options to patients where surgery and chemotherapy hasn’t worked or could be used alongside them. We now need to start trials with these treatments, but we hope this could make a real difference to people with mouth cancer in the future.”

FRMD4A switches on a process that helps cancer cells group and stick together. When it is deactivated, this cell ‘stickiness’ is lost and ultimately causes cancer cells to die.  

Lead author, Professor Fiona Watt, said: “We hope that our approach would be more effective and specific than treating the pathway that FRMD4A is involved in, but we now need to test new potential drugs to see if this will work in patients.”

The researchers were looking at a particular type of – head and neck squamous cell carcinoma – which is an aggressive form of the disease.

Around 50 per cent of people with this type of cancer survive for at least five years, but despite new treatments and radical surgery this figure has not improved for the past 30 years.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: “This research offers a number of approaches that we can now explore to help treat these cancers, including blocking the directly. These cancers often return and spread so it’s vital we find new ways to treat them more effectively.”

Explore further: Scientists find new drug target for hard-to-treat leukaemia

More information: Goldie SJ (2012). FRMD4A Upregulation in Human Squamous Cell Carcinoma Promotes Tumor Growth and Metastasis and Is Associated with Poor Prognosis. Cancer research PMID: 22564525. cancerres.aacrjournals.org/con … /72/13/3424.abstract

Related Stories

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012
(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

March 6, 2012
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

Scientists discover how antibiotic molecule found in bacteria stops breast cancer

August 22, 2011
(Medical Xpress) -- Scientists have discovered how a molecule that was first discovered in bacteria blocks a protein which causes breast cancer to develop and spread, reveals research published in Nature Chemistry today.

Scientists expose important new weak spot in cancer cells

December 5, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that cancer cells can ‘bag up and bin’ a toxic protein to cheat death – revealing a new Achilles heel in cancer cells that could be targeted ...

Aspirin's 'double hit' on bowel cancer

June 1, 2012
(Medical Xpress) -- Aspirin kills cancer cells by controlling two key processes that influence energy use in cells and could explain how aspirin can prevent bowel cancer. The research is published in this month’s Gastroenterology.

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.